Human alveolar lining fluid from the elderly promotes *Mycobacterium tuberculosis* growth in alveolar epithelial cells and bacterial translocation into the cytosol

Angélica M. Olmo-Fontáñez^{1,2}, Julia M. Scordo^{1,3}, Andreu Garcia-Vilanova¹, Diego Jose Maselli⁴, Jay I. Peters⁴, Blanca I. Restrepo⁵, Daniel L. Clemens⁶, Joanne Turner¹, Larry S. Schlesinger¹, and Jordi B. Torrelles¹

¹Population Health and Host Pathogen Interactions Programs, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. ²Integrated Biomedical Sciences Program, University of Texas Health Science Center at San Antonio, TX, 78229, USA. ³Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, 78229, USA. ⁴Division of Pulmonary and Critical Care Medicine, School of Medicine, University of Texas Health Science Center at San Antonio, TX, 78229, USA. ⁵University of Texas Health Science Center at Houston, School of Public Health, Brownsville campus, Brownsville, TX 78520, USA; and South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Edinburg, TX 78541, USA; ⁶University of California, Los Angeles Health Sciences, Los Angeles, CA, 90095, USA.

Corresponding Author: Dr. Jordi B. Torrelles, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. Email: jtorrelles@txbiomed.org.

Conflict of interest: The authors declare no conflict of interest.

Running Title: Human lung mucosa influences *M.tb* growth in ATs.

Keywords: *Mycobacterium tuberculosis*; aging; alveolar epithelial cells; alveolar lining fluid; cytosol; tuberculosis.

ABSTRACT

The elderly population is at significant risk of developing respiratory diseases, including tuberculosis (TB) caused by the airborne *Mycobacterium tuberculosis* (*M.tb*). Once *M.tb* reaches the alveolar space, it contacts alveolar lining fluid (ALF) which dictates host cell interactions. We previously determined that age-associated dysfunctionality in human ALF soluble innate components lead to accelerated *M.tb* growth within human alveolar macrophages. Here we determined the impact of human ALF on *M.tb* infection of alveolar epithelial cells (ATs), another critical cellular determinant of infection. We observed that E-ALF-exposed *M.tb* had significantly increased intracellular growth in ATs compared to adult ALF (A-ALF)-exposed bacteria. Despite this, there were no alterations in AT inflammatory mediators or cell activation. However, exposure to E-ALF altered endosomal trafficking of *M.tb*, driving bacterial translocation to both endosomal and cytosolic compartments in ATs. Our results indicate that exposure of *M.tb* to E-ALF promotes translocation of bacteria into the AT cytosol as a potential favorable niche for rapid bacterial growth and at the same time dampens AT's immune responses. Thus, our findings highlight the influence of the elderly lung mucosa on *M.tb* infection of ATs, an unexplored contributing factor to the elderly population's increased susceptibility of developing active TB disease.

51 INTRODUCTION

52 Tuberculosis (TB) is one of the leading causes of death due to an infectious disease and is
 53 considered a global threat killing over 4,500 people every day.¹ The risk of TB susceptibility and
 54 mortality is significantly increased in individuals aged 65 and older.^{2, 3} TB is caused by airborne
 55 *Mycobacterium tuberculosis* (*M.tb*), transmitted primarily by inhalation, where it is deposited into
 56 the distal portion of the airways and alveoli. In this environment, *M.tb* encounters the lung
 57 mucosa, or alveolar lining fluid (ALF), which contains soluble innate factors such as surfactant
 58 proteins A and D (SP-A/SP-D), hydrolytic enzymes, complement, lipids, and others, which
 59 activate subsequent innate and adaptive immune responses.⁴⁻⁶

60
 61 As we age, changes to soluble components of the innate immune system in ALF may contribute
 62 to the increased susceptibility of the elderly population to TB.^{7, 8} Published studies from our labs
 63 found that ALF from elderly humans and old mice have increased levels of pro-inflammatory and
 64 pro-oxidative mediators, impacting *M.tb* infection outcomes *in vitro* and *in vivo*.⁹ Human
 65 macrophages infected with *M.tb* exposed to elderly human ALF (E-ALF) have reduced control
 66 of infection and altered intracellular trafficking with fewer phagosome–lysosome fusion events.
 67 These observations were reversed when E-ALF was replenished with functional SP-A/SP-D,
 68 supporting the importance of the functionality of ALF innate components in *M.tb* control.⁹ This
 69 was also observed *in vivo*, where *M.tb* that had been exposed to E-ALF grew faster and induced
 70 more lung immunopathology in young infected mice.⁹

71
 72 Most studies focus on the role of ALF in altering *M.tb*-phagocyte interactions;^{4, 10, 11} however, it
 73 is critical to understand the impact of ALF on *M.tb* infection of non-professional phagocytes, in
 74 particular, alveolar epithelial type cells (ATs).^{12, 13} ATs are the most prevalent cell population that
 75 covers the internal surface area of the alveolar environment.¹⁴ The alveolar epithelium contains

76 two main epithelial cell types that maintain alveolus integrity, preventing microbial dissemination.
 77 Type I ATs are the most abundant cell type, providing a structural role in shaping the alveolus
 78 and allowing for gas exchange.¹⁴ Type II ATs are spherical pneumocytes that comprise less than
 79 5% of the surface area yet constitute 60% of the ATs and play an essential role in host defense
 80 and in maintaining alveolar homeostasis by secreting and recycling ALF components such as
 81 surfactant proteins, hydrolases, and mucosal antibodies, among others.¹⁵⁻¹⁷
 82
 83 When *M.tb* reaches the alveoli it first interacts with ATs and alveolar macrophages, with
 84 subsequent invasion and replication within the alveolar epithelial barrier.¹⁸ *M.tb* expresses a
 85 variety of virulence factors such as a heparin-binding hemagglutinin (HBHA) and malate
 86 synthase that promote adherence and entry into ATs.^{19, 20} Given that ATs are non-professional
 87 phagocytes, they are proposed to provide a protective niche that enables *M.tb* to replicate and
 88 elude an innate immune response. Nonetheless, ATs also participate in immune responses
 89 involved in controlling *M.tb* infection by producing pro-inflammatory cytokines (TNF, IL-8, and
 90 GM-CSF), thereby potentiating cellular crosstalk and activation of alveolar macrophages leading
 91 to an increase in their antimycobacterial activity.²¹ An additional host defense mechanism of ATs
 92 is the secretion of innate immune molecules, e.g., SP-A, SP-D, complement component 3 (C3),
 93 antimicrobial peptides, antibodies, and hydrolases, among others into the ALF that exhibits an
 94 essential role facilitating cell recruitment, microbial killing¹⁶ and even driving the differential
 95 outcome of *M.tb* infection in ATs.¹³ We recently found that *M.tb* exposed to ALF from healthy
 96 adults vary in growth rates within ATs, which was dependent on ALF protein oxidation levels and
 97 function.¹³ Based on these findings and our characterization of the elderly lung environment, we
 98 aimed to determine the impact of the elderly lung mucosa on *M.tb* infection of ATs. We provide
 99 evidence that *M.tb* exposure to E-ALF drives increased *M.tb* replication and growth in ATs, as
 100 well as *M.tb* translocation to both endosomal and cytosolic compartments in ATs, keeping

unaltered AT cell death and early immune responses against the infection. These findings indicate that E-ALF promotes *M.tb* growth within ATs potentially by exploiting the AT cytosol as a protective replicative niche for *M.tb*.

RESULTS

M.tb* exposure to elderly human ALF drives increased bacterial intracellular growth in alveolar epithelial cells (ATs) *in vitro

Our prior studies have shown that *M.tb* exposure to ALF from elderly individuals (E-ALF) accelerates the growth of *M.tb* within human alveolar macrophages and human monocyte-derived macrophages.⁹ Here we observed that *M.tb* previously exposed to E-ALF also demonstrates significantly increased intracellular growth in ATs when compared to A-ALF-exposed *M.tb* (**Fig. 1A**). This increased bacterial growth of E-ALF-exposed *M.tb* was not due to differences in the inoculum used and/or uptake by ATs, because the inoculum of *M.tb* exposed to E-ALF or A-ALF and levels of uptake were equivalent (**Fig. 1B-C**). We further confirmed that intracellular growth differences within ATs were not due to changes in AT cell viability after infection with *M.tb* exposed to either A-ALF or E-ALF over the infection period (120 h) (**Suppl. Fig. S1**). We next explored the surface expression of e-Cadherin (CD324) on ATs in the different treatment groups. Our results showed high e-Cadherin expression throughout the infection, indicating that cell-cell interfaces between ATs were stable,²² consistent with high cell viability (data not shown). Together these data provide evidence for enhanced E-ALF-*M.tb* intracellular growth in ATs compared to bacteria exposed to A-ALF.

We next determined the rate of bacterial replication of A-ALF vs. E-ALF-exposed *M.tb* during AT infection, using the fluorescent replication reporter SSB-GFP, smyc':mCherry *M.tb* strain. This *M.tb* reporter contains a single-stranded DNA binding protein that allows for the quantification of

actively replicating bacteria.²³ Our results indicate that E-ALF-exposed *M.tb* have enhanced replication at 24 h post-AT infection (**Fig. 2**), which supports the increased growth of E-ALF *M.tb* within ATs over time (**Fig. 1A**). This increase in replication was observed until 72 h post-infection; however, at this time point, both A-ALF and E-ALF had a similar replication rate (**Fig. 2A**).

E-ALF exposure decreases *M.tb* bacilli trafficking to late endosomes within ATs

Differential trafficking of *M.tb* within ATs may allow for bacterial evasion of killing or serve as a host killing mechanism,¹³ depending on cellular location. Using GFP expressing *M.tb*, we quantified co-localization of A-ALF vs. E-ALF-exposed *M.tb* with AT intracellular markers visualized by laser scanning confocal microscopy: Rab5 is an early endosomal marker, Rab7 is a late endosomal marker, LC3 is a marker of autophagosomes, LAMP-1 and CD63 are lysosomal markers, and ABCA1 (marker of multivesicular bodies) and ABCA3 (marker of lamellar bodies) are ATP-binding cassette lipid transporters. E-ALF-exposed *M.tb* demonstrated significantly decreased co-localization events for the late endosomal marker, Rab7, at 72 hours post-infection (**Fig. 3**). Single co-localizations of Rab5 (and not Rab7) with GFP expressing *M.tb* were not detected, consistent with previous studies in which at just 4 h post-infection nearly all *M.tb* bacilli were associated with Rab7 positive compartments.²⁴ For the remainder of the intracellular markers studied (lysosome LAMP-1 and CD63, autophagosome LC3, multivesicular body ABCA1, lamellar body ABCA3), there were no significant differences in the percentage of A-ALF-exposed GFP *M.tb* co-localization events vs. E-ALF-exposed GFP *M.tb* co-localization events, at 72 hours post-infection (**Fig. 4**). Moreover, A-ALF or E-ALF-exposed *M.tb* were in equivalent acidified vacuoles as indicated by their co-localization with LysoTracker-Red (**Fig. 5**). Overall, exposure to E-ALF significantly decreases trafficking of *M.tb* to late endosomes within ATs.

E-ALF-exposed *M.tb* has increased cytosolic location in infected ATs

While it is well accepted that *M.tb* traffics through the endosomal pathway in phagocytic cells, less is known about *M.tb* intracellular localization within non-phagocytic cells such as ATs. Bacteria, including *M.tb*, can escape from phagosomes into the host cell cytosol as an alternative mechanism of survival within phagocytes.^{25, 26} Our results indicate that, at 72 hours after infection, A-ALF-exposed *M.tb* is primarily located in endosomal/lysosomal (vacuoles) compartments in ATs using transmission electron microscopy (TEM) (**Fig. 6**). In contrast, a much greater percentage of E-ALF-exposed *M.tb* was observed in the cytosol (56.3% vs. 16.9%) (**Fig. 6A**). The designation of cytosolic bacteria was determined by a lack of vacuolar (endosomal) membranes surrounding bacteria (**Fig. 6B**). Together, the TEM and confocal microscopy results define the overall location distribution of E-ALF and A-ALF-exposed *M.tb* within AT intracellular compartments (**Fig. 6C**), demonstrating that the majority of A-ALF-exposed *M.tb* remain in late endosomal compartments while E-ALF-exposed bacteria are increasingly present in the cytosol. We speculate that increased translocation of *M.tb* from the endosome to the cytosol for E-ALF-exposed *M.tb* may represent one mechanism by which the bacteria are able to have increased intracellular growth in ATs.

Effect of A- and E-ALF-*M.tb* on AT surface marker expression

ATs are the major structural cell population of the alveolar environment¹⁴ and, active participants in lung immunity. ATs can activate infiltrating myeloid cells and lymphocytes by acting as antigen-presenting cells through surface expression of major histocompatibility complexes I and II (MHC I/II).^{27, 28} In this regard, at 24 h post-infection, we observed a higher percentage of HLA-ABC (MHC Class I) expression in both A-ALF and E-ALF-*M.tb*-infected ATs in comparison with HLA-DR/DP/DQ (MHC Class II) (**Fig. 7**), and this expression increased over time (120 h) (**Fig. 7A; Suppl. Fig. S2A**). Moreover, A-ALF *M.tb*-infected ATs showed an increase (compared with

uninfected ATs) in the percentage of surface expression and MFI values for HLA-DR/DP/DQ over time although the data did not reach statistical significance (**Fig. 7B**; **Suppl. Fig. S2B**). Interestingly, HLA-DR/DP/DQ expression in E-ALF *M.tb*-infected ATs remained unchanged with respect to uninfected ATs (**Fig. 7B**), which could derive in less T cell activation in the elderly. Thus, we observed that both E-ALF and A-ALF-*M.tb* drive similar MHC surface markers expression in ATs.

Effect of A-ALF and E-ALF-*M.tb* on the production of immune mediators

Considering that *M.tb* exposure to E-ALF drives increased intracellular bacterial growth in ATs, we tested whether E-ALF-exposed *M.tb* increase levels of AT pro-inflammatory cytokines and chemokines, reflecting increased AT activation. We quantified the production of immune mediators responsible for immune cell infiltration toward the site of infection and/or for promoting immune cell proliferation and maturation in the AT cultures.²⁹ Both A-ALF and E-ALF-exposed *M.tb* infection induced mainly pro-inflammatory cytokines by ATs when compared to uninfected ATs, which was maintained over time (up to 120 h studied). This increasing trend was the case for TNF and IL-6, with IL-18 reaching significant levels (**Fig. 8A**). Significant production of chemokines was also observed from AT cultures infected with A-ALF and E-ALF-exposed *M.tb* compared to uninfected ATs. This was particularly the case for the following chemokines: CCL2/MCP-1, CCL5/RANTES, and IL-8/CXCL8 at later time points post-infection (**Fig. 8B**). GM-CSF also was significantly produced at later time-points (**Fig. 8B**). Overall, we did not observe significant differences in AT immune mediator production during infection between A-ALF or E-ALF-exposed *M.tb*. Thus, exposure to E-ALF enhances *M.tb* replication and growth in ATs without altering cell activation compared to A-ALF-exposed bacteria.

200

201 DISCUSSION

202 TB remains one of the top 10 causes of death worldwide.¹ The elderly population (65 years or
 203 older) with inherent compromise in immunity is at higher risk of developing active TB disease.³
 204 Additionally, the elderly may have additional comorbidities (e.g., diabetes, hyperglycemia, HIV
 205 co-infection, malnutrition, smoking, among others) that would make them even more vulnerable
 206 to primary *M.tb* infection and reactivation of a latent infection to active TB disease.^{3, 30, 31}
 207 Therefore, it is critical to study how the lung environment changes as we age, and the impact of
 208 these changes on the establishment of respiratory infections, such as *M.tb*. We have published
 209 that the elderly lung mucosa contains many oxidized proteins and constitutes an inflammatory
 210 environment, with dysfunctional surfactant proteins and complement function.⁹ Moreover, we
 211 have established that upon contacting the elderly lung mucosa, *M.tb* replicates faster in human
 212 macrophages and has increased bacterial burden *in vivo* in C57BL/6 mice, inducing increased
 213 lung tissue damage.⁹ Here we determined that after exposure to the elderly lung mucosa or E-
 214 ALF, *M.tb* infects alveolar epithelial cells (ATs), the major non-phagocytic cell of the alveolar
 215 space, equivalently to A-ALF-exposed *M.tb*. However, E-ALF exposed bacteria replicated faster
 216 inside ATs. This finding was associated with the fact that E-ALF-exposed bacteria were found
 217 to a much greater extent in the cytosol, suggesting that this location is a favorable niche for the
 218 bacteria to establish infection, averting host immune response (**Fig. 9**).

219

220 Once *M.tb* reaches the alveolar space, it is recognized by resident or recruited phagocytes,
 221 including alveolar macrophages, dendritic cells, and/or neutrophils.³² Although *M.tb* uptake by
 222 phagocytes does not always lead to clearance of infection, macrophages from elderly individuals
 223 are more permissive to intracellular growth.^{2, 33} Another cell population particularly crucial in the
 224 early stages and outcomes of *M.tb* infection are the non-professional phagocytes ATs.^{15, 34} ATs

line the alveolar epithelium forming a physical barrier that prevents rapid invasion and plays a critical role in host defense to control *M.tb* infection.^{15, 32} One of the significant roles is the production of components within the alveolar mucosa, or alveolar lining fluid (ALF), composed of a surfactant monolayer and an aqueous hypophase surrounding alveolar compartment cells.¹⁵ We have shown that innate soluble components of ALF, including homeostatic hydrolytic enzymes, modify the *M.tb* cell envelope and allow for better recognition by cells of the immune system.⁴⁻⁶ In this regard, it remains unclear if E-ALF-exposed *M.tb* infection of ATs alters their production of ALF innate soluble components, which would also impact the outcome of infection in the elderly.

Our group has previously published that ALF from elderly individuals have increased levels of pro-inflammatory and pro-oxidative mediators.⁹ Furthermore, human macrophages infected with elderly human ALF-exposed *M.tb* had reduced control of infection.⁹ Considering that most studies focus only on the role of ALF in altering *M.tb*-phagocyte interactions, we aimed to determine the impact of the adult and elderly lung mucosa on *M.tb* infection of ATs. Here, we show that *M.tb* exposure to human E-ALF drove significantly increased intracellular bacterial growth in ATs. This finding supports the importance of ALF in old age which has a different composition⁷ in enhancing *M.tb* infection by allowing *M.tb* to replicate faster in both alveolar phagocytic⁹ and non-phagocytic cells. Our results also indicate that E-ALF-exposed *M.tb* does not activate ATs; nor kill them, enabling the continued growth of E-ALF-exposed *M.tb* within ATs over time.

The *M.tb* phagosome in macrophages shares features with early endosomes due to blockage of EEA1 and Rab7 recruitment,^{35, 36} whereas *M.tb* was found to traffic to late endosomes in epithelial cells.³⁷ Our results are consistent with previous studies in which *M.tb* vacuoles in

250 alveolar and bronchial epithelial cell lines resides mainly in Rab7 positive compartments.^{24, 37}
 251 Notably, exposure to E-ALF decreased *M.tb* endosome association with Rab7 in late endosomes
 252 in ATs. In this regard, we found similar results in ATs infected with higher MOIs (data not shown).
 253 Our data showed no significant differences in the percentage of co-localization events of A-ALF
 254 or E-ALF-exposed *M.tb* within additional AT intracellular compartments (*i.e.*, LAMP-1, CD63,
 255 LC3, ABCA1, ABCA3) consistent with our previous studies showing that *M.tb* bacilli exposed to
 256 different human A-ALFs did not have altered intracellular trafficking in those compartments within
 257 ATs.¹³ Here we further explored the location of *M.tb* within ATs by TEM to better understand the
 258 differences in intracellular growth and trafficking. We found that E-ALF-exposed *M.tb* are located
 259 in both vacuolar and cytosolic compartments, whereas A-ALF-exposed *M.tb* bacilli are located
 260 mainly in vacuoles, where ATs could potentially better control their replication and growth.

261
 262 Several studies performed in macrophages have shown how *M.tb* can employ different
 263 mechanisms of survival, including, inhibition of phagosome-lysosome fusion,³⁸ suppression of
 264 the autophagy pathway³⁹ and escape from phagosomes into the cytosol.^{25, 26} However,
 265 trafficking patterns of *M.tb* in ATs seem to differ as *M.tb* is contained mainly in late (Rab7)
 266 endosomal compartments and lysosomal fusion with late endosomes is inhibited, supporting its
 267 increased survival within ATs.³⁷ In this regard, we note that *M.tb* bacilli traffic to late endosomes
 268 in ATs, but upon exposure to E-ALF, *M.tb* decreased association with Rab7 positive
 269 compartments as it translocated into the cytosol, a potential niche to increase its replication rate.

270
 271 The autophagy pathway is an alternative killing mechanism against intracellular pathogens when
 272 they escape from the typical phagosome/lysosome fusion killing mechanism.^{40, 41} Since E-ALF-
 273 exposed *M.tb* was located in the cytosol where there is a high bacterial replication rate, we
 274 explored if autophagy was attenuated in ATs infected with E-ALF-exposed *M.tb*. Our results

275 indicate that A-ALF and E-ALF exposure did not alter *M.tb* bacilli trafficking to autophagosomes
 276 (no differences in LC3 positive compartments) within ATs. Although autophagy has been
 277 described as an alternative killing mechanism of *M.tb* in macrophages, it could also play an
 278 opposite role in mycobacterial trafficking in ATs if it fails to eliminate the bacterial burden.³⁷ In
 279 fact, inactivation of the autophagy pathway using 3-methyladenine decreased *M.tb* intracellular
 280 growth and was advantageous for ATs survival.³⁷ Lastly, exclusively pathogenic mycobacteria
 281 species, including *M.tb*, are reported to translocate from the phagolysosome into the cytosol
 282 facilitated by the ESAT-6 secretion complex-1 (ESX-1 type VII secretion system) in
 283 macrophages.⁴² While more studies are needed to elucidate whether the *M.tb* ESX-1 type VII
 284 secretion system also mediates *M.tb* translocation into the cytosol in non-professional
 285 phagocytes, *M.tb* genes encoding ESAT-6 proteins are upregulated during *M.tb* infection of
 286 ATs.⁴³ Given that E-ALF exposure promoted *M.tb* growth within ATs and greater translocation
 287 to the cytosol we speculate this may be a mechanism for better survival of *M.tb* in ATs. Ongoing
 288 studies in our lab are focused on determining the *M.tb* metabolic status within ATs at the time of
 289 its translocation into the cytosol to elucidate the bacterial mechanism involved in this process.

290

291 Additional mechanisms that ATs may use to contribute to the innate and adaptive immune
 292 responses after *M.tb* infection are, first, bacterial uptake by recognition and binding of microbial
 293 associated molecular patterns present on the *M.tb* surface;³² and second, modulation of the cell
 294 to cell crosstalk by the production of immune mediators.^{29, 34} We have found that *M.tb* infected
 295 ATs secrete some cytokines (e.g. IL-18), but mainly chemoattractants (e.g. CCL2,
 296 CCL5/RANTES, and IL-8) at later time points post-infection. Some of these immune mediators
 297 are significantly induced by E-ALF-exposed vs. A-ALF-exposed *M.tb* (e.g. CCL5/RANTES) and
 298 are critical to the initiation of local inflammatory responses, mainly cell recruitment (e.g.
 299 neutrophils), and activation of host innate cells and even induction of cell-mediated immunity

300 after *M.tb* infection, which could unbalance local immunity towards favoring *M.tb* infection spread
301 being detrimental for the host.³⁴

302

303 Here we show that during infection in ATs, E-ALF-exposed *M.tb* induced similar changes in
304 surface marker expression or in the production of immune mediators when compared to A-ALF-
305 exposed *M.tb*, possibly hindering alveolar compartment cells activation, infiltration, and
306 differentiation. Indeed, when compared to uninfected cells, E-ALF-exposed *M.tb* did not induce
307 the expression of MHC-II on the AT surface, potentially negatively influencing T cell activation.
308 Altogether, our data reveal that *M.tb* exposure to the inflammatory E-ALF environment which
309 contains an array of oxidized proteins^{7, 9} enhances *M.tb* intracellular growth in ATs, while
310 promoting translocation of bacteria to the AT cytosol as a potential niche for establishing and
311 propagating *M.tb* infection. Our study highlights the impact of elderly lung mucosa on *M.tb*
312 infection of ATs, critical non-professional phagocytes that impact TB as well as other respiratory
313 infectious diseases.

314

315

316 MATERIALS AND METHODS

317 ***Ethics Statement and Human Subjects*** - Human subject studies were carried out in strict
318 accordance with the US Code of Federal and Local Regulations (OSU Institutional review board
319 (IRB) numbers 2012H0135, and 2008H0119 and Texas Biomedical Research Institute/UT-
320 Health San Antonio/ South Texas Veterans Health Care System IRB number HSC20170673H.
321 Bronchoalveolar lavage fluid (BALF) from healthy adults (aged 18-45 years) and elderly (aged
322 60 years and older) individuals were recruited from both sexes without discrimination of race or
323 ethnicity after informed written consent. See Supplementary Information for details.

324

325 **Human ALF isolation** - ALF was obtained and concentrated from human bronchoalveolar
 326 lavage fluid (BALF) from healthy adults and elderly donors. ALF was normalized as previously
 327 described,^{4, 9, 11} to obtain the physiological concentration present within the lung (at 1 mg/mL of
 328 phospholipid). Briefly, BAL was performed in sterile 0.9% NaCl, filtered (0.2 µm pore size sterile
 329 filter system), and subsequently concentrated 20-fold by using a 10-kDa molecular mass cutoff
 330 membrane Centricon Plus (Amicon Bioseparations) device at 4°C, aliquoted in low protein
 331 binding-sterile tubes and stored at -80°C.

332

333 **AT culture** - For all experimental procedures, we utilized the human ATs type II-like cell line
 334 A549 (ATCC® CCL-185™) as a lung carcinoma cell line that exhibits most AT type II cells traits
 335 (model of ATs). Cell cultures were prepared as we previously described¹³ with minor changes.
 336 Briefly, the A549 cell line was cultured at 37 °C with 5% CO₂ in DMEM/F12 supplemented with
 337 10% FBS (Atlas Biologicals, Fort Collins, CO) and 1% PenStrep (Sigma, St. Louis, MO), allowing
 338 at least three weeks of passages prior to use in experiments. Cells were maintained in antibiotic-
 339 free growth medium one week before doing *M.tb* infection.

340

341 ***M.tb* cultures** - *M.tb* H₃₇R_v-Lux (27294) (kindly provided by Drs. Abul Azad and Larry
 342 Schlesinger, Texas Biomedical Research Institute) was grown as described.^{44, 45} SSB-GFP,
 343 smyc::mCherry *M.tb* Erdman (kindly provided by Dr. David Russell, Cornell University) was
 344 grown as described.²³ GFP-*M.tb* Erdman (kindly provided by Dr. Marcus Horwitz, UCLA) was
 345 grown as previously described.⁴ Single bacterial suspensions were prepared as we described.^{9,}

346 13

347

348 **Exposure of *M.tb* bacteria to human ALF** - Preparation of adult and elderly ALF-exposed *M.tb*
 349 was performed as we previously described.^{10, 11, 13} ALF-exposed *M.tb* inoculums were serially
 350 diluted in 7H9 broth and plated on 7H11 agar to determine *M.tb* viability and specifically to
 351 confirming no differences in viable bacterial counts among E-ALF vs. A-ALF-exposed *M.tb*.

352

353 ***M.tb* infection and luciferase-based intracellular growth of ATs** - *M.tb* infection of ATs was
 354 performed as previously described.¹³ Briefly, single cell suspensions of *M.tb* in DMEM/F12/FBS
 355 media were added to the ATs culture at various MOIs, and cells were incubated for 2 h with the
 356 first 30 min on a platform shaker. After infection, unbound bacteria were removed by washing,
 357 and gentamicin (50 µg/mL)-supplemented medium was added for 1 h to kill extracellular
 358 bacteria. Following this, cells were washed and incubated with 10 µg/mL gentamicin-
 359 supplemented medium for the indicated times. For luciferase-based *M.tb* growth assays,⁴⁵ ATs
 360 were infected with *M.tb* H₃₇R_V-Lux, and bacterial bioluminescence was measured every 24 h for
 361 up to 120 h with a GloMax Multi Detection System (Promega, Madison, WI). For the *M.tb*
 362 replication rate experiment, ATs were infected with SSB-GFP, smyc::mCherry *M.tb* Erdman
 363 strain. For intracellular trafficking, acidification assay, and electron microscopy experiments, ATs
 364 were infected with GFP-*M.tb* Erdman (GFP, 488 nm) strain.

365

366 **AT cell viability assay** - At indicated times post-infection, AT cytotoxicity was determined by
 367 CellTiter-Glo® luminescent cell viability assay (Promega Cat. #G7570) following the
 368 manufacturer's instructions. See Supplementary Information for details.

369

Immunocytochemistry and Confocal Microscopy - ATs monolayers on glass coverslips were infected for 2 h with A-ALF- or E-ALF-exposed *M.tb* at MOI 10:1 and processed as described.¹³ Briefly, at 72 hours post-infection, ATs were fixed with cold 4% paraformaldehyde for 15 min at room temperature and permeabilized with 0.1% Triton-X100 in PBS for 10 min at room temperature. To evaluate the *M.tb* intracellular trafficking, cellular compartments were stained with primary Abs in confocal blocking buffer (5 mg/ml BSA, 5% HI-FBS, 10% donkey serum, 0.03% Triton X-100) for overnight incubation at 4°C. Following this, the secondary Abs or matched isotype controls were incubated for 1 h at 37°C.

Intracellular markers used were Rab5A (early endosomal marker; mouse anti-human Rab5A; 1:200; Cell Signaling Technology Cat. #46449), Rab7 (late endosomal marker; rabbit anti-human Rab7; 1:100; Cell Signaling Technology Cat. #9367), LAMP-1 (lysosomal marker; mouse anti-human LAMP-1; 2 µg/ml; DSHB Cat. #P11279), CD63 (lysosomal marker; mouse anti-human CD63; 1 µg/ml; BD Biosciences Cat. #556019), LC3-II (autophagy marker; rabbit anti-human LC3; 1:200; Cell Signaling Technology Cat. #3868), ABCA1 (ATP-binding cassette lipid transporter marker of multivesicular bodies; mouse anti-human ABCA1; 5 µg/ml; Abcam Cat. #ab18180) and, ABCA3 (lamellar bodies ABC transporter marker; rabbit anti-human ABCA3; 2 µg/ml; Abcam Cat. #ab99856). Secondary Abs were donkey anti-rabbit IgG H&L conjugated to Alexa Fluor® 647 (Abcam Cat. #ab150063) and donkey anti-mouse IgG H&L conjugated to Alexa Fluor® 568 (Abcam Cat. #ab175700). Negative controls were included to check for non-specific binding and false-positive results, including wells incubated with isotypes control antibodies or in which primary Abs were omitted. Isotype controls were mouse IgG1 isotype (Abcam Cat. #ab91353) and rabbit IgG isotype (Invitrogen Cat. #26102). The nucleus was stained with 50 ng/ml 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen Cat. #D1306) for 10 min

393 at room temperature. After multiple washes to remove the excess of DAPI solution, coverslips
394 were mounted on slides using ProLong Gold Antifade Reagent (Invitrogen Cat. #P36934).

395 Cells were visualized by laser scanning confocal microscopy using ZEISS LSM 800 microscope
396 set at appropriate parameters and a final magnification of 600X. Co-localization events of the
397 different cellular compartments containing GFP-*M.tb* Erdman was quantified by counting at least
398 100 events per condition in duplicate. All microscopy data were analyzed with Zeiss ZEN
399 Software.

400

401 **AT compartment acidification assay** - AT compartment acidification was determined by
402 LysoTracker-Red® assay (Invitrogen Cat. #L7528), at 72 hours post-infection following the
403 manufacturer's instructions. See Supplementary Information for details.

404

405 **Transmission electron microscopy** - ATs monolayers were infected for 2 h with A-ALF-
406 exposed *M.tb* or E-ALF-exposed *M.tb* at MOI 100:1 and processed as mentioned previously.
407 Infected ATs, at 72 hours post-infection were fixed in 2.5% glutaraldehyde and 2% formaldehyde
408 (in 0.1 M Na Cacodylate pH 7.3) and analyzed by transmission electron microscopy (TEM) as
409 previously described^{46, 47} with minor changes. See Supplementary Information for details.

410 Samples were shipped to Dr. Daniel L. Clemens, an expert in the study of intracellular
411 compartmentalization of *M.tb* by TEM for analyses in a blinded manner.⁴⁸⁻⁵⁰ The main objective
412 was to quantify the relative proportion of bacilli located within membrane-bound vesicles or
413 located in the cytosol compartment (lacking membrane bilayers around the bacilli). For each
414 condition, at least 100 events were imaged and scored in a blinded fashion using the JEOL

415 100CX transmission electron microscope (BRI Electron Microscopy Core Facility; Brain
416 Research Institute UCLA).

417

418 **Expression of AT surface markers by flow cytometry** - Following infection at different time
419 points, ATs were stained with LIVE/DEAD (L/D) Fixable Dead Cell Kit (Invitrogen Cat. # L23105)
420 following manufacturer's instructions, and a panel of surface markers or matched isotype
421 controls in deficient RPMI buffer, for 10 min in the dark at 4°C. Recombinant fluorescently-
422 labelled Abs used were VioBlue HLA-ABC (1:50; REAfinity™ Cat. #130-120-435), PE HLA-
423 DR/DP/DQ (1:50; REAfinity™ Cat. #130-120-715), APC CD324 [e-Cadherin] (1:50; REAfinity™
424 Cat. #130-111-840); and isotypes controls were VioBlue human IgG1 (1:50; REAfinity™ Cat.
425 #130-113-442), PE human IgG1 (1:50; REAfinity™ Cat. #130-113-438) and, APC human IgG1
426 (1:50; REAfinity™ Cat. #130-113-434). Cells were then washed, fixed with 4% PFA, and follow
427 by consequent washes before stored overnight at 4°C until analysis. Samples were analyzed
428 using a FACSymphony A3 flow cytometer (BD Biosciences). Each sample for analysis contained
429 5,000–100,000 events, and dead cells were subsequently gated out according to their L/D
430 staining. All flow cytometry data were analyzed using FlowJo Version 10.6.2 software (FlowJo,
431 LLC).

432

433 **AT cytokine and chemokine production** - Protein levels in supernatants from infected (*A-M.tb*
434 and *E-M.tb*) or non-infected ATs were determined using a multiplex panel human magnetic bead
435 Luminex® Assay for IL-6, CCL5/Rantes, GM-CSF, TNF- α , IL-1 β , IL-18/IL-1F4, IL-10 and IL-
436 12/IL-23 (R&D, Human 10-Plex Cat. #LXSAHM-10, Lot #L134898); and using Human enzyme-
437 linked immunosorbent assay (ELISA) kits for IL-8/CXCL8 (dilution 1:5; R&D Cat. # DY208-05,
438 Lot #P105639) and CCL2/MCP-1 (dilution 1:15; R&D Cat. # DY279-05, Lot #333900) following

the manufacturer's instructions. Human Luminex analysis was performed using Luminex200 (SN LX10009028406) with a xPONENT 4.3 Software version with the following parameters: DD gate 8,000-16,500, 50 μ l of sample volume, 50-100 events per bead/region, and Low PMT (LMX100/200: Default). All cytokines and chemokines analyses were measured at 24 h and 120 h post-infection. Some cytokines/chemokines levels were out of range, mainly reporting lower values. The dashed line (LLOQ and HLOQ) in those graphs indicates that the analyte levels are not necessary quantitatively determined with suitable accuracy.

Statistical Analysis - An unpaired, 2-tailed Student's *t*-Test for two-group comparisons was determined to assess statistical significance using GraphPad Prism 8 Software. In these studies, "n" values represent the number biological replicas using a different ALF sample from different adult or elderly human donors. Statistical differences between groups were reported as significant (*) when the p-value is less than or equal to 0.05.

ACKNOWLEDGEMENTS

This study was supported by the National Institute on Aging (NIA), National Institutes of Health (NIH) (Grant number P01 AG-051428 to J.T., J.B.T., B.I.R and L.S.S.), and J.B.T. was partially supported by Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation. The research reported in this publication was also partially supported by the Office of the Director, NIH under Award Number S10OD028653. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A.M.O.-F. was supported by the Douglass Graduate Fellowship at Texas Biomedical Research Institute.

462

463 **AUTHOR CONTRIBUTIONS**

464 A.M.O.-F. and J.B.T. contributed to the design of the studies. A.M.O.-F., J.M.S. and A.G.-V.
 465 contributed to the experimental procedures. A.M.O.-F. and J.M.S. contributed to the acquisition
 466 of data and data analyses. J.I.P. and D.J.M. performed bronchoalveolar lavages (BAL) and
 467 provided the BAL fluid samples. D.L.C. provided TB-transmission electron microscopy expertise
 468 and scoring the samples by blinded analysis. J.B.T., L.S.S., J.T., D.L.C. and B.I.R provided a
 469 critical analysis of the data and editing of manuscript. A.M.O.-F. and J.B.T. wrote the manuscript.

470

471

472 **ADDITIONAL INFORMATION**

473 **Supplementary information:** The online version contains supplementary material available at
 474 <https://doi.org/10.1101/2021.05.12.443884>

475 **Competing interests:** The authors declare no competing interests.

476

477

478

479

480

481

482

REFERENCES

1. Martini, M., Barberis, I., Gazzaniga, V. & Icardi, G. The fight to end tuberculosis: a global challenge in strong partnership. *J Prev Med Hyg.* **61** (1 Suppl 1), E1-E2 (2020).
2. Guerra-Laso, J. M. *et al.* Macrophages from elders are more permissive to intracellular multiplication of *Mycobacterium tuberculosis*. *Age (Dordr).* **35** (4), 1235-1250 (2013).
3. Schaaf, H. S., Collins, A., Bekker, A. & Davies, P. D. Tuberculosis at extremes of age. *Respirology.* **15** (5), 747-763 (2010).
4. Arcos, J. *et al.* Human Lung Hydrolases Delineate *Mycobacterium tuberculosis*-Macrophage Interactions and the Capacity to Control Infection. *J Immunol.* **187** (1), 372-381 (2011).
5. Ferguson, J. S., Voelker, D. R., McCormack, F. X. & Schlesinger, L. S. Surfactant protein D binds to *Mycobacterium tuberculosis* bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. *J Immunol.* **163**, 312-321 (1999).
6. Gaynor, C. D. *et al.* Pulmonary surfactant protein A mediates enhanced phagocytosis of *Mycobacterium tuberculosis* by a direct interaction with human macrophages. *J Immunol.* **155** (11), 5343-5351 (1995).
7. Moliva, J. I. *et al.* Molecular composition of the alveolar lining fluid in the aging lung. *Age (Dordr).* **36** (3), 9633 (2014).
8. Piergallini, T. J. & Turner, J. Tuberculosis in the elderly: Why inflammation matters. *Exp Gerontol.* (2017).
9. Moliva, J. I. *et al.* The Lung Mucosa Environment in the Elderly Increases Host Susceptibility to *Mycobacterium tuberculosis* Infection. *J Infect Dis.* **220** (3), 514-523 (2019).
10. Arcos, J. *et al.* *Mycobacterium tuberculosis* Cell Wall released Fragments by the Action of the Human Lung Mucosa modulate Macrophages to Control Infection in an IL-10-Dependent Manner. *Mucosal Immunol.* **10** (5), 1248-1258 (2017).
11. Scordo, J. M. *et al.* *Mycobacterium tuberculosis* Cell Wall Fragments Released upon Bacterial Contact with the Human Lung Mucosa Alter the Neutrophil Response to Infection. *Front Immunol.* **8**, 307 (2017).
12. Bermudez, L. E. & Goodman, J. *Mycobacterium tuberculosis* Invades and Replicates within Type II Alveolar Cells. *Infect Immun.* **64**, 1400-1406 (1996).
13. Scordo, J. M. *et al.* The human lung mucosa drives differential *Mycobacterium tuberculosis* infection outcome in the alveolar epithelium. *Mucosal Immunol.* **12**, 795-804 (2019).

14. Ward, H. E. & Nicholas, T. E. Alveolar type I and type II cells. *Aust N Z J Med.* **14** (5 Suppl 3), 731-734 (1984).
15. Fehrenbach, H. Alveolar epithelial type II cell: defender of the alveolus revisited. *Respir Res.* **2** (1), 33-46 (2001).
16. Torrelles, J. B. & Schlesinger, L. S. Integrating Lung Physiology, Immunology, and Tuberculosis. *Trends Microbiol.* **25** (8), 688-697 (2017).
17. Olmo-Fontáñez, A. M. & Torrelles, J. B. Alveolar Epithelial Cells. In *Advances in Host-Directed Therapies Against Tuberculosis* (Karakousis PC, Hafner R, Gennaro ML, eds) 247-255. (Springer International Publishing, Cham, 2021).
18. Bermudez, L. E. *et al.* The Efficiency of the Translocation of *Mycobacterium tuberculosis* across a Bilayer of Epithelial and Endothelial cells as a Model of the Alveolar Wall Is a Consequence of Transport within Mononuclear Phagocytes and Invasion of Alveolar Epithelial Cells. *Infect Immun.* **70** (1), 140-146 (2002).
19. Menozzi, F. D. *et al.* Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. *Proc Natl Acad Sci USA.* **95**, 12625-12630 (1998).
20. Kinshikar, A. G. *et al.* Mycobacterium tuberculosis malate synthase is a laminin-binding adhesin. *Mol Microbiol.* **60** (4), 999-1013 (2006).
21. Sato, K. *et al.* Type II alveolar cells play roles in macrophage-mediated host innate resistance to pulmonary mycobacterial infections by producing proinflammatory cytokines. *J Infect Dis.* **185** (8), 1139-1147 (2002).
22. Carterson, A. J. *et al.* A549 lung epithelial cells grown as three-dimensional aggregates: alternative tissue culture model for *Pseudomonas aeruginosa* pathogenesis. *Infect Immun.* **73** (2), 1129-1140 (2005).
23. Sukumar, N., Tan, S., Aldridge, B. B. & Russell, D. G. Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. *PLoS Pathog.* **10** (9), e1004394 (2014).
24. Harrieff, M. J. *et al.* Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8(+) T cells. *PLoS ONE.* **9** (5), e97515 (2014).
25. Jamwal, S. V. *et al.* Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism. *Sci Rep.* **6**, 23089 (2016).
26. van der Wel, N. *et al.* *M. tuberculosis* and *M. leprae* translocate from the phagolysosome to the cytosol in myeloid cells. *Cell.* **129** (7), 1287-1298 (2007).
27. Chuquimia, O. D. *et al.* The role of alveolar epithelial cells in initiating and shaping pulmonary immune responses: communication between innate and adaptive immune systems. *PLoS ONE.* **7** (2), e32125 (2012).

580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627

28. Corbiere, V. *et al.* Phenotypic characteristics of human type II alveolar epithelial cells suitable for antigen presentation to T lymphocytes. *Respir Res.* **12**, 15 (2011).
29. Scordo, J. M., Knoell, D. L. & Torrelles, J. B. Alveolar Epithelial Cells in *Mycobacterium tuberculosis* Infection: Active Players or Innocent Bystanders? *J Innate Immun.* **8** (1), 3-14 (2016).
30. Menon, S. *et al.* Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population. *BMC Infect Dis.* **16**, 361 (2016).
31. Feng, J. Y. *et al.* Impact of cigarette smoking on latent tuberculosis infection: does age matter? *Eur Respir J.* **43** (2), 630-632 (2014).
32. Lerner, T. R., Borel, S. & Gutierrez, M. G. The innate immune response in human tuberculosis. *Cell Microbiol.* **17** (9), 1277-1285 (2015).
33. Lafuse, W. P. *et al.* Identification of an Increased Alveolar Macrophage Subpopulation in Old Mice That Displays Unique Inflammatory Characteristics and Is Permissive to *Mycobacterium tuberculosis* Infection. *J Immunol.* **203** (8), 2252-2264 (2019).
34. Li, Y., Wang, Y. & Liu, X. The Role of Airway Epithelial Cells in Response to *Mycobacteria* Infection. *Clin Dev Immunol.* **2012**, 791392 (2012).
35. Fratti, R. A. *et al.* Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. *J Cell Biol.* **154** (6), 631-644 (2001).
36. Via, L. E. *et al.* Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. *J Biol Chem.* **272**, 13326-13331 (1997).
37. Fine, K. L. *et al.* Involvement of the autophagy pathway in trafficking of *Mycobacterium tuberculosis* bacilli through cultured human type II epithelial cells. *Cell Microbiol.* **14** (9), 1402-1414 (2012).
38. Sturgill-Koszycki, S. *et al.* Lack of acidification in *Mycobacterium* phagosomes produced by exclusion of the vesicular proton-ATPase. *Science.* **263**, 678-681 (1994).
39. Ouimet, M. *et al.* *Mycobacterium tuberculosis* induces the miR-33 locus to reprogram autophagy and host lipid metabolism. *Nat Immunol.* **17** (6), 677-686 (2016).
40. Gutierrez, M. G. *et al.* Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages. *Cell.* **119** (6), 753-766 (2004).
41. Schmid, D. *et al.* Autophagy in innate and adaptive immunity against intracellular pathogens. *J Mol Med (Berl).* **84** (3), 194-202 (2006).

42. Houben, D. *et al.* ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. *Cell Microbiol.* **14** (8), 1287-1298 (2012).
43. Ryndak, M. B., Singh, K. K., Peng, Z. & Laal, S. Transcriptional profile of *Mycobacterium tuberculosis* replicating in type II alveolar epithelial cells. *PLoS One.* **10** (4), e0123745 (2015).
44. Arnett, E. *et al.* PPARgamma is critical for *Mycobacterium tuberculosis* induction of Mcl-1 and limitation of human macrophage apoptosis. *PLoS Pathog.* **14** (6), e1007100 (2018).
45. Salunke, S. B. *et al.* Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. *Bioorg Med Chem.* **23** (9), 1935-1943 (2015).
46. Kushida, H. Propylene Oxide as a Dehydrating Agent for Embedding with Epoxy Resins. *Journal of Electronmicroscope.* **10** (3), 203-204 (1961).
47. Glauert, A. M. *Fixation, Dehydration and Embedding of Biological Specimens.* 1st edn.(Elsevier Science 1975).
48. Clemens, D. L. Characterization of the *Mycobacterium tuberculosis* phagosome. *Trends Microbiol.* **4** (3), 113-118 (1996).
49. Clemens, D. L., Lee, B. Y. & Horwitz, M. A. Deviant expression of Rab5 on phagosomes containing the intracellular pathogens *Mycobacterium tuberculosis* and *Legionella pneumophila* is associated with altered phagosomal fate. *Infect Immun.* **68** (5), 2671-2684 (2000).
50. Clemens, D. L., Lee, B.-Y. & Horwitz, M. A. *Mycobacterium tuberculosis* and *Legionella pneumophila* phagosomes exhibit arrested maturation despite acquisition of Rab7. *Infect Immun.* **68** (9), 5154-5166 (2000).

FIGURE LEGENDS

Figure 1. Exposure of *M.tb* to elderly human ALF is associated with increased bacterial intracellular growth in ATs. ATs were infected with ALF-exposed *M.tb* (H₃₇R_V-Lux) for 2 h at Multiplicity of Infection (MOI) of 10:1 followed by 1 h of gentamicin to kill extracellular *M.tb*. **(A)** Infected monolayers in 96-well plates were read for increased luminescence (indicative of *M.tb* H₃₇R_V-Lux intracellular growth in ATs) over time (up to 120 h), using the GLOMAX reading system. **(B)** No differences in bacteria inoculum between conditions. **(C)** No differences in bacteria uptake by ATs after 2 h post-infection. Overall data of n=4 experiment in triplicate [Mean ± SEM], using four different A-ALFs and E-ALFs. Student's unpaired *t*-Test; Adult vs Elderly, *p<0.05, **p<0.01, ***p<0.001, ns: no significant differences. A: Adult ALF-exposed *M.tb* (white bar), E: Elderly ALF-exposed *M.tb* (black bar), RLUs: Relative Lux Units; "n" values represent the number biological replicas using a different ALF sample from different adult or elderly human donors.

Figure 2. Elderly ALF-exposed *M.tb* has enhanced early replication during ATs infection. ATs were infected with the reporter SSB-GFP, smyc':mCherry *M.tb* strain for up to 72 h, and *M.tb* replication rate was determined by confocal microscopy. **(A)** Percentage of SSB+*M.tb* exposed to A- and E-ALFs at 24 h and 72 h post-infection, n=2-4 [Mean ± SEM], using two different A-ALFs and four different E-ALFs. **(B)** Representative confocal images of ATs infected with A- and E-ALF-*M.tb* at 72 h post-infection. The region indicated by gray dashed-line is shown expanded on the right (top panels, A-ALF; bottom panels, E-ALF). Replicating SSB+*M.tb* are indicated by white arrowheads, showing merged (yellow) foci. Events were enumerated by counting at least 50 independent events, in replicates. Student's unpaired *t*-Test; Adult vs Elderly, *p<0.05, **p<0.01, ***p<0.001, ns: no significant differences. A: Adult exposed *M.tb*, E:

693 Elderly exposed *M.tb*; “n” values represent the number biological replicas using a different ALF
694 sample from different adult or elderly human donors.

695

696 **Figure 3. E-ALF drive decrease *M.tb* bacilli trafficking late endosomes within ATs.** ATs
697 were infected with either A-ALF or E-ALF-exposed GFP *M.tb* for 2 h at Multiplicity of Infection
698 (MOI) of 10:1 followed by 1 h of gentamicin to kill extracellular *M.tb*. Monolayers were stained
699 with different intracellular markers at 72 h post-infection. (A) Semi-quantification of
700 Rab5+Rab7+*M.tb* (indicative of *M.tb* movement from early to late endosomes) co-localization
701 events and Rab7+*M.tb* co-localization events (indicative of *M.tb* already in late endosomes),
702 n=3, using three different A-ALFs and E-ALFs. (B) Representative confocal images of ATs
703 infected with A- and E-ALF-*M.tb* stained with intracellular markers Rab5 and Rab7. Events were
704 enumerated by counting at least 100 independent events, in duplicate [Mean ± SEM]. The region
705 indicated by gray dashed-line is shown expanded on the right; and co-localization events are
706 indicated by white arrowheads. Open arrowheads indicate double co-localization events
707 (Rab5+Rab7+). Student’s unpaired *t*-Test; Adult vs Elderly, *p<0.05, **p<0.01, ***p<0.001, ns:
708 no significant differences. A: Adult exposed *M.tb*, E: Elderly exposed *M.tb*, DIC: Differential
709 Interference Contrast, DAPI: 4',6-diamidino-2-phenylindole (ATs nuclear DNA); “n” values
710 represent the number biological replicas using a different ALF sample from different adult or
711 elderly human donors.

712

713 **Figure 4. A-ALF and E-ALF does not alter *M.tb* additional intracellular trafficking within**
714 **ATs.** ATs were infected with either A-ALF or E-ALF-exposed GFP *M.tb* for 2 h at Multiplicity of
715 Infection (MOI) of 10:1 followed by 1 h of gentamicin to kill extracellular *M.tb*. Stained with
716 different intracellular markers at 72 h post-infection. (A) Semi-quantification of LAMP-1+*M.tb* co-
717 localization events (indicative of *M.tb* in lysosomes) and LC3+*M.tb* co-localization events

(indicative of *M.tb* in autophagosomes), n=5, using five different A-ALFs and E-ALFs. **(B)** Representative confocal images of ATs infected with A- and E-ALF-*M.tb* stained with intracellular markers LAMP-1 and LC3. **(C)** Semi-quantification of CD63+*M.tb* co-localization events (indicative of *M.tb* in lysosomes), n=3, using three different A-ALFs and E-ALFs. **(D)** Representative confocal images of ATs infected with A- and E-ALF-*M.tb* stained with intracellular marker CD63. **(E)** Semi-quantification of ABCA1+*M.tb* co-localization events (indicative of *M.tb* in multivesicular bodies) and ABCA3+*M.tb* co-localization events (indicative of *M.tb* in lamellar bodies), n=3, using three different A-ALFs and E-ALFs. **(F)** Representative confocal images of ATs infected with A- and E-ALF-*M.tb* stained with intracellular markers ABCA1 and ABCA3. Events were enumerated by counting at least 100 independent events, in duplicate [Mean $\pm$ SEM]. The region indicated by gray dashed-line is shown expanded on the right; and co-localization events are indicated by white arrowheads. Student's unpaired *t*-Test; Adult vs Elderly, **p*<0.05, ***p*<0.01, ****p*<0.001, ns: no significant differences. A: Adult exposed *M.tb*, E: Elderly exposed *M.tb*, DIC: Differential Interference Contrast, DAPI: 4',6-diamidino-2-phenylindole (ATs nuclear DNA); n" values represent the number biological replicas using a different ALF sample from different adult or elderly human donors.

734

Figure 5. Similar acidification rates of intracellular compartments containing A- and E-ALF-exposed *M.tb*. **(A)** Semi-quantification of LysoTracker+*M.tb* acidification events, n=6 [Mean $\pm$ SEM], using six different A-ALFs and E-ALFs in infected ATs after 72 h. **(B)** Representative confocal images showing ALF-exposed GFP *M.tb* (top panels, A-ALF; bottom panels, E-ALF) co-localization with LysoTracker (red). Gray dashed-line box region is shown expanded on the right, with acidified events (yellow) indicated by white arrowheads. Events were enumerated by counting at least 100 independent events, in duplicate. Student's unpaired *t*-Test; Adult vs Elderly, **p*<0.05, ***p*<0.01, ****p*<0.001, ns: no significant differences. A: Adult

exposed *M.tb*, E: Elderly exposed *M.tb*, DIC: Differential Interference Contrast, DAPI: 4',6-diamidino-2-phenylindole (ATs nuclear DNA); “n” values represent the number biological replicas using a different ALF sample from different adult or elderly human donors.

Figure 6. ALF-exposed *M.tb* drives differences in intracellular localization within ATs.

Relative proportion of intracellular bacteria located within a membrane-bound vesicles or free in the cytosol by TEM. **(A)** Coded samples were scored by blinded analysis to quantify A-ALF- and E-ALF-exposed *M.tb* located in vacuolar (endosomal/lysosomal) or cytosolic compartments, n=2. **(B)** Transmission electron micrographs of ALF-exposed *M.tb*. Adult ALF and Elderly ALF-exposed *M.tb* were scored as “cytosolic” if they were not enclosed within a membrane, or scored as “vacuolar” if they were surrounded by a vacuolar membrane. Vacuole membranes are indicated by black arrowheads. Bacteria are indicated by asterisks. Values were determined by counting at least 100 independent events (bacteria), in replicate [Mean ± SEM]. Student’s unpaired *t*-Test; *p<0.05, **p<0.01, ***p<0.001, ns (or absence of line): no significant differences. A-V: Adult ALF-exposed *M.tb* in vacuolar compartment (Size bar 400 nm and 800 nm, respectively), A-C: Adult ALF-exposed *M.tb* in cytosolic compartment (Size bar 400 nm), E-V: Elderly ALF-exposed *M.tb* in vacuolar compartment (Size bar 600 nm and 200 nm, respectively), E-C: Elderly ALF-exposed *M.tb* in cytosolic compartment (Size bar 400 nm and 600 nm, respectively). **(C)** Normalized cellular compartment distribution of E-ALF-exposed vs. ALF-exposed *M.tb* within ATs; “n” values represent the number biological replicas using a different ALF sample from different adult or elderly human donors.

Figure 7. Effect of A- and E-ALF-*M.tb* on AT surface markers expression.

Surface expression of uninfected and infected ATs with either A-ALF or E-ALF-exposed *M.tb* were measured by flow cytometry. **(A)** Percentage of HLA-ABC (MHC Class I) expression overtime.

768 **(B)** Percentage of HLA-DR/DP/DQ (MHC Class II) expression overtime. Data shown are n=3
 769 [Mean $\pm$ SEM], using three different A-ALFs and E-ALFs. Student's unpaired *t*-Test; Adult vs
 770 Elderly, **p*<0.05, ***p*<0.01, ****p*<0.001, ns (or absence of line): no significant differences. A:
 771 Adult exposed *M.tb*, E: Elderly exposed *M.tb*, UI: Uninfected ATs; "n" values represent the
 772 number biological replicas using a different ALF sample from different adult or elderly human
 773 donors.

774

775 **Figure 8. Effect of A- and E-ALF-*M.tb* on the production of ATs immune mediators.** ATs
 776 supernatants from uninfected and infected ATs with either A-ALF or E-ALF-exposed *M.tb* were
 777 tested for cytokines **(A)** and chemokines **(B)** production and measured over time by Luminex
 778 multiplex assay following the manufacturer's instructions. Cell supernatants tested were
 779 undiluted and the data shown are n=5 (using five different A-ALFs and E-ALFs) and n=2
 780 (uninfected ATs conditions). For CCL-2/MCP-1 and IL-8/CXCL8 cell supernatants were diluted
 781 1:15 and 1:5, respectively, and measured over time by ELISA kits following the manufacturer's
 782 instructions. Student's unpaired *t*-Test [Mean $\pm$ SEM]; Adult vs Elderly, **p*<0.05, ***p*<0.01,
 783 ****p*<0.001, ns (or absence of line): no significant differences. A: Adult exposed *M.tb*, E: Elderly
 784 exposed *M.tb*, UI: Uninfected ATs, ND: Not detectable, LLOQ: Low limit of quantification, HLOQ:
 785 High limit of quantification.

786

787 **Figure 9. Schematic overview of the main findings in this study.** *Mycobacterium*
 788 *tuberculosis* (*M.tb*) exposure to alveolar lining fluid (ALF) from elderly individuals enhances
 789 intracellular growth in alveolar epithelial cells (ATs). Moreover, ATs infection with E-ALF-
 790 exposed *M.tb* does not show altered production of inflammatory mediators (cytokines and
 791 chemokines) or cell activation. A-ALF-exposed *M.tb* is mainly located in endosomal/lysosomal
 792 (vacuoles) controlling its growth, but interestingly, E-ALF-exposed *M.tb* appears to be located in

793 both vacuolar and cytosolic compartments. Overall, E-ALF seemingly promotes *M.tb* growth
794 within ATs, preventing cell activation, and potentially exploiting the AT cytosol as a niche for
795 survival. This illustration was created with BioRender (<https://biorender.com/>).

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

Figure 1

Figure 2

A

B

Figure 3

Figure 4

Figure 4 (Cont.)

Figure 4 (Cont.)

E

F

Figure 5

A

B

Figure 6

Figure 6 (Cont.)

C

Figure 7

Figure 8

A

B

CCL2/MCP-1 (24 h) CCL2/MCP-1 (120 h)

CCL5/Rantes (24 h) CCL5/Rantes (120 h)

IL-8/CXCL8 (24 h) IL-8/CXCL8 (120 h)

GM-CSF (24 h) GM-CSF (120 h)

Figure B displays eight bar charts showing the levels of various cytokines (pg/mL) for three groups (A, E, UI) at two time points (24 h and 120 h). The charts are arranged in a 4x2 grid. Each chart includes a dashed line representing the LLOQ (Lower Limit of Quantification). Statistical significance is indicated by asterisks (*) and p-values.

CCL2/MCP-1 (24 h)

Group	pg/mL
A	~320
E	~360
UI	~320

CCL2/MCP-1 (120 h)

Group	pg/mL
A	~850
E	~850
UI	~500

p=0.0628

CCL5/Rantes (24 h)

Group	pg/mL
A	~300
E	~250
UI	~100

CCL5/Rantes (120 h)

Group	pg/mL
A	~1500
E	~3000
UI	~100

*

IL-8/CXCL8 (24 h)

Group	pg/mL
A	~300
E	~300
UI	~150

**

IL-8/CXCL8 (120 h)

Group	pg/mL
A	~5000
E	~5000
UI	~1500

*

GM-CSF (24 h)

Group	pg/mL
A	~2.2
E	~2.3
UI	~2.5

GM-CSF (120 h)

Group	pg/mL
A	~3.3
E	~3.5
UI	~2.2

p=0.0852

Figure 9